Effect of low dose antioxidant vitamin and trace element supplementation on the urinary concentrations of thromboxane and prostacyclin metabolites.
OBJECTIVE
This trial evaluated the effect of antioxidant supplementation on the urinary excretion of 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio, a marker of the pathogenesis of thrombosis and arteriosclerosis.


METHODS
This study was a randomised, double-blind, placebo-controlled trial involving 186 presumably healthy volunteers. One hundred received a multi-antioxidant supplementation and 86 a placebo for two years. Blood zinc, selenium, beta-carotene, vitamin C and E and urinary excretion of 11-dehydro TXB(2) and 2,3 dinor 6 keto PGF(1alpha) were measured.


RESULTS
Baseline subject characteristics did not differ between the two groups. Blood zinc, selenium, and beta-carotene concentrations significantly increased between baseline and two years in the multi-antioxidant supplementation group supporting subject compliance (p < 0.05). At two years, the median urinary 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio was significantly lower in the multi-antioxidant supplementation group (3.4 versus 2.78, p = 0.015). Serum selenium concentration was the only antioxidant studied that was significantly related to the urinary 11-dehydro TXB(2)/2,3 dinor 6 keto PGF(1alpha) ratio.


CONCLUSIONS
These results support the hypothesis that a low-dose multi-antioxidant supplementation may contributes to a reduction in platelet activation which is beneficial for cardiovascular function.
Arnaud
Josiane
J
Département de Biologie Intégrée, CHU de Grenoble, BP 217, 38043 Grenoble cedex 9, France. JArnaud@chu-grenoble.fr
Bost
Muriel
M
Vitoux
Dominique
D
Labarère
José
J
Galan
Pilar
P
Faure
Henri
H
Hercberg
Serge
S
Bordet
Jean-Claude
JC
Roussel
Anne-Marie
AM
Chappuis
Philippe
P
D015121:6-Ketoprostaglandin F1 alpha / Q000031:analogs & derivatives / Q000652:urine; D000975:Antioxidants / Q000008:administration & dosage / Q000378:metabolism*; D001161:Arteriosclerosis / Q000097:blood / Q000517:prevention & control; D015415:Biomarkers / Q000652:urine; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D015539:Platelet Activation / Q000187:drug effects; D044062:Prostaglandins I / Q000652:urine*; D012643:Selenium / Q000008:administration & dosage / Q000097:blood; D013927:Thrombosis / Q000097:blood / Q000517:prevention & control; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D013931:Thromboxanes / Q000652:urine*; D014131:Trace Elements / Q000008:administration & dosage / Q000378:metabolism*; D014815:Vitamins / Q000008:administration & dosage / Q000378:metabolism*; D015032:Zinc / Q000008:administration & dosage / Q000097:blood; D019207:beta Carotene / Q000008:administration & dosage / Q000097:blood
D000975:Antioxidants; D015415:Biomarkers; D044062:Prostaglandins I; D013931:Thromboxanes; D014131:Trace Elements; D014815:Vitamins; D019207:beta Carotene; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; C028290:2,3-dinor-6-ketoprostaglandin F1alpha; C049235:11-dehydro-thromboxane B2; D012643:Selenium; D015032:Zinc